araag2/HINT huggingface dataset:
Clinical trial NCT01127542 (phase 2, status: terminated)
Conditions: chronic lymphocytic leukaemia
ICD codes: A87.2, K52.832, D72.111, C91.11, C91.12, C91.10
Drugs: lenalidomide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    potential safety issue of second primary malignancies in patients treated with lenalidomide.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Binet stage A CLL

          -  2 or more risk factors:

          -  Unmutated IgVH locus (≥98% homology to germline sequence)

          -  CD38 expression (>7%)

          -  Deletion of chromosome 11q22 (>20% by FISH)

          -  Deletion of chromosome 17p13 (>10% by FISH)

          -  Over 18 years old

          -  Capable to provide written informed consent

          -  ECOG performance status < 2

          -  Life expectancy > 2 years

          -  Must agree to not share lenalidomide with someone else

          -  Must agree not to donate blood whilst taking the study drug and for one week after
             discontinuation of treatment.

          -  Female subjects of childbearing potential and all male subjects must agree to comply
             with the stipulations of the pregnancy prevention plan.

        Exclusion Criteria:

          -  Current or recent (within the last 1 month) participation in another clinical trial
             investigating the action of an investigational medicinal product for the treatment of
             CLL

          -  Pregnant or lactating

          -  Known positivity for human immunodeficiency virus (HIV) types 1 or 2

          -  Prior history of malignancies, other than CLL, unless the subject was treated with
             curative intent and has been free of the disease for ≥3 years. Exceptions include the
             following:

          -  Basal cell carcinoma of the skin

          -  Squamous cell carcinoma of the skin

          -  Carcinoma in situ of the cervix

          -  Carcinoma in situ of the breast

          -  Significantly abnormal renal or hepatic function (creatinine clearance < 60ml/min,
             serum aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), serum
             bilirubin > 34μmol/l)

          -  Laboratory tumour lysis syndrome according to the Cairo-Bishop classification.
             Subjects may be enrolled when these abnormalities have been corrected.

          -  Peripheral neuropathy (grade ≥ 2)

          -  Previous treatment for CLL

          -  Previous treatment with Thalidomide or immunomodulatory derivative drugs (including
             Lenalidomide)

          -  Treatment with corticosteroids (for CLL or other indications) < 28 days from study
             entry

          -  Evidence of Richter's transformation

          -  Unsupported absolute neutrophil count < 1x109/l or platelet count < 50x10*9/l not due
             to CLL

          -  Active autoimmune haemolytic anaemia or thrombocytopenia

          -  Any other medical or psychological condition that in the view of the investigator
             would be likely to impact compliance with the protocol or interfere with trial
             treatment.
Clinical trial NCT00142168 (phase 2, status: terminated)
Conditions: waldenstrom's macroglobulinemia
ICD codes: C88.0
Drugs: cc-5103 (lenalidomide), rituximab
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Clinicopathological diagnosis of Waldenstrom's macroglobulinemia using consensus panel
             criteria

          -  Age 18 years or older

          -  CD20 positive based on any previous bone marrow immunohistochemistry or flow
             cytometric analysis

          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must
             have been discontinued at least 4 weeks prior to treatment in this study

          -  Measurable disease, defined as presence of immunoglobulin M paraprotein with a minimum
             IgM level of equal to or greater than 2 times the upper limit of normal.

          -  ECOG performance status of 0-2

          -  Absolute neutrophil count ≥ 100,000,000/L

          -  Platelet count ≥ 50,000,000,000/L

          -  Hemoglobin > 8 g/dL

          -  Serum creatinine < 2.5 mg/dL

          -  Total bilirubin < 1.5 mg/dL

          -  AST and ALT < 2.5 x ULN

          -  Disease free of prior malignancies fir 5 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or
             breast

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness

          -  Pregnant or lactating women

          -  Prior therapy with rituximab or CC-5103

          -  Known hypersensitivity to thalidomide

          -  Development of erythema nodosum if characterized by a desquamating rash while taking
             thalidomide or similar drugs.

          -  Concurrent use of other anti-cancer agents or treatments
Clinical trial NCT00501241 (phase 2, status: terminated)
Conditions: chronic constipation
ICD codes: K59.04
Drugs: ati-7505, ati-7505, ati-7505, ati-7505, ati-7505
SMILES: CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1, CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1, CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1, CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1, CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  written informed consent

          -  18 and 75 years of age

          -  constipation symptom onset at least 6 months ago & meet ROME III criteria for chronic
             constipation

          -  negative colonoscopy or air contrast barium enema within the past 2 years if ≥50 years
             of age or within the past 5 years if <50 years of age;

          -  are able to refrain from use of medications known to treat constipation or associated
             symptoms throughout the study

        Exclusion Criteria:

          -  transabdominal surgery, unstable coronary artery disease, organic gastrointestinal
             disease, collagen vascular disease, or any alarm symptoms within the 6 months prior to
             screening;

          -  taking prohibited medications (including laxatives, herbal remedies)

          -  participating in another drug or medical device study or use of any investigational
             drug within 30 days before dosing or planning to use prior to study completion;

          -  QTcB >440 msec, abnormal 12-lead ECG, family history of sudden death at age <40 years
             or history of long QT syndrome

          -  alcohol or drug abuse within the 6 months prior to screening;

          -  autonomic dyssynergic defecation
Clinical trial NCT00533351 (phase 2, status: terminated)
Conditions: neuralgia
ICD codes: G50.0, M54.81, B02.22, M79.2
Drugs: agn201781, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study was terminated early due to low enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia

          -  Moderate or severe pain associated with postherpetic neuralgia or post-traumatic
             peripheral neuralgia

        Exclusion Criteria:

          -  Women of child-bearing potential

          -  Any other uncontrolled diseases
Clinical trial NCT00136487 (phase 2/phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of prostate cancer

          -  Progression following prostatectomy or radiation to the prostate, defined as 3 PSA
             rises, with each PSA determination at least 4 weeks apart

          -  PSA greater than or equal to 1.0 for men who had a prostatectomy

          -  PSA greater than or equal to 3.0 for men who were treated with primary radiation
             therapy (external beam and/or brachytherapy)

          -  PSA doubling time between 6 and 24 months

          -  Participants must be either fully active and asymptomatic or symptomatic but fully
             ambulatory

          -  Adequate bone marrow function, kidney function and liver function as evidenced by
             laboratory results

        Exclusion Criteria:

          -  Evidence of metastatic disease

          -  Prior hormonal therapy for recurrent prostate cancer

          -  Prior chemotherapy for recurrent or metastatic prostate cancer

          -  Radiation therapy within 6 months

          -  Patients allergic to non-steroidal anti-inflammatory drugs (NSAIDs), salicylates or
             sulfonamide-type medications who experience asthma or urticaria (hives) after taking
             aspirin or other NSAIDs

          -  Patients taking a dose of aspirin greater than or equal to 325 mg a day within 4 weeks
             of study entry

          -  Patients taking selective COX-2 inhibitors or any NSAIDs other than aspirin within 8
             weeks of study entry

          -  Patients taking fluconazole, lithium or warfarin

          -  History of gastrointestinal or abdominal ulceration or any history of significant
             gastrointestinal bleeding in the past 12 months

          -  Any history of myocardial infarction in the past 12 months

          -  Any uncontrolled, serious medical or psychiatric illness
Clinical trial NCT00401882 (phase 2, status: terminated)
Conditions: cardiac arrest, sudden cardiac death, ventricular fibrillation, tachycardia, ventricular
ICD codes: I97.120, I97.710, I46.9, P29.81, I46.2, I97.121, I97.711, Z82.41, I49.01, I47.2
Drugs: epinephrine, metoprolol
SMILES: CNC[C@H](O)C1=CC(O)=C(O)C=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Reason stopped: 
    difficult accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  All patients age > 18 years of age who develop an in-hospital VF or pVT arrest which
             persists after three or more precordial shocks.

          -  Patients who develop an in-hospital cardiac arrest due to asystole or PEA which
             subsequently converts to VF or pVT will be included.

        Exclusion Criteria:

          -  Pediatric patients

          -  Pregnancy

          -  Age < 18 years of age

          -  Patients who develop VF or pVT in the emergency room, operating room or surgical
             intensive care unit.
Clinical trial NCT01281631 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: np001, np001, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Subjects with sporadic or familial ALS classified as definite, probable, or
        laboratory-supported probable ALS according to the revised El Escorial criteria. A list of
        key criteria is listed below:

        Inclusion Criteria:

          -  Onset of symptoms less than 3 years prior to study entry.

          -  Forced Vital Capacity (FVC) at least 70% of that predicted for age and height.

          -  Stable dose of riluzole if undergoing treatment with this agent.

          -  For females: Not be of childbearing potential or agree to use adequate birth control
             during the study.

        Exclusion Criteria:

          -  Unstable medical condition(s) other than ALS.

          -  Life expectancy of less than 6 months.

          -  Require life-sustaining interventions for the 6 months following randomization.

          -  Have a tracheotomy or be using ventilatory assistance [including Bi-level Positive
             Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)].

          -  Active pulmonary disease.

          -  Immune modulator therapy within 12 weeks of study entry or participation in studies of
             other agents within the last 4 weeks prior to the randomization.
Clinical trial NCT00642746 (phase 2, status: terminated)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: erlotinib, fluorouracil, leucovorin, oxaliplatin, irinotecan
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.
  
Eligibility criteria:

        Inclusion Criteria:

        Patients must fulfill all of the following criteria to be eligible for study entry:

          -  Age 18-80

          -  Able to provide informed consent

          -  Biopsy proven unresectable metastatic adenocarcinoma of the colon or rectum

          -  Documented progression on prior first-line oxaliplatin-based or irinotecan-based
             regimen for metastatic colorectal cancer

          -  Radiographically measurable disease with at least one bidimensionally measurable
             lesion of > 1 cm

          -  Prior first-line regimen must have been completed at least 4 weeks prior to study
             treatment

          -  Use of biologic agents with first-line chemotherapy permitted

          -  Previous adjuvant regimens must have been greater than 6 months before inclusion

          -  Adequate organ function including bone marrow, liver and renal function as defined by
             the following values: absolute neutrophil count > 1500/microliter; Hgb > 9 g/dL;
             platelets > 90,000/microliter; International Normalized Ratio < 1.8 (unless in
             therapeutic range if taking warfarin or other warfarin-derivative anticoagulants and
             are being monitored regularly for changes in prothrombin time or International
             Normalized Ratio); bilirubin < 2 times the Upper Limit of Normal; alkaline phosphatase
             < 3 times the Upper Limit of Normal; aspartate aminotransferase/alanine
             aminotransferase < 5 times the Upper Limit of Normal; serum creatinine < 1.5 times the
             Upper Limit of Normal

          -  Eastern Cooperative Oncology Group status < 2

        Exclusion Criteria:

        Patients meeting any of the following criteria are ineligible for study entry:

          -  Prior second-line chemotherapy regimens for colorectal cancer

          -  Prior treatment with erlotinib or gefitinib

          -  Central Nervous System metastasis

          -  Second malignancies less than 5 years prior to enrollment. Completely resected basal
             or squamous cell carcinoma of the skin is allowed.

          -  Untreated/unresolved bowel obstruction

          -  Inability to take oral mediations

          -  HIV positive

          -  Pregnancy

          -  Other uncontrolled medical illnesses

          -  Current diarrhea > grade 2

          -  Symptomatic angina or uncontrolled congestive heart failure
Clinical trial NCT00097409 (phase 2, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ispinesib
SMILES: CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Must have a screening CA-125 of greater than or equal to 40 U/ml.

          -  Must have received only one prior platinum/taxane-based chemotherapy regimen.

          -  Blood tests will be done to check if blood counts are adequate for taking part in the
             study.

        Exclusion criteria:

          -  Received more than 1 chemotherapy regimen in the past or have less than adequate liver
             and kidney function.

          -  Females who are pregnant or nursing.

          -  Any unstable, pre-existing major medical condition or history of other cancers.

          -  Have received an investigational drug, chemotherapy, radiation treatment or surgery
             within 28 days prior to entering the study.
Clinical trial NCT00216099 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented adenocarcinoma of the prostate

          -  Clinically refractory or resistant to hormone therapy as assessed by progression
             following at least one hormonal therapy (orchiectomy or luteinizing hormone-releasing
             hormone (LHRH) agonist)

          -  One prior taxane based chemotherapy regimen for HRPC

          -  Documented progression of disease after one taxane based prior chemotherapy regimen
             for HRPC. Progression is defined as at least one of the following:

          -  An increase in PSA > 50% over nadir value on prior Taxane-based therapy

          -  Progression of measurable disease as defined by RECIST

          -  Progression of bone disease as defined by the appearance of one or more new bone
             lesions or worsening symptoms

          -  Orchiectomy or testosterone levels < 50 ng/dL maintained by LHRH agonist

          -  Prior chemotherapy, or other experimental anticancer agents must be completed > 4
             weeks prior to being registered for protocol therapy

          -  Palliative radiotherapy must be completed at least 14 days prior to registration.

        Exclusion Criteria:

          -  Intravenous radio-isotopes therapy must be completed at least 6 weeks prior to
             registration

          -  No brain metastasis that are untreated and/or not controlled and/or still requiring
             corticosteroids

          -  No history of other malignancies within 5 years prior to being registered for protocol
             therapy, except for adequately treated basal or squamous cell skin cancer

          -  No history of uncontrolled psychiatric illness or serious systemic disease, including
             active infection, uncontrolled hypertension

          -  No surgery or significant traumatic injury within 21 days prior to being registered
             for protocol therapy

          -  Patients must be willing to interrupt aspirin or other non-steroidal anti-inflammatory
             agents for a 5-day period (8 day period for long acting agents such as piroxicam)

          -  Patients must be willing to take folic acid or vitamin B12 supplementation
Clinical trial NCT01425814 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: las100977, las100977, las100977, las100977, reference, placebo
SMILES: O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males and non-pregnant, non-lactating females aged 40 or older.

          2. Patients with a clinical diagnosis of COPD, according to the GOLD guidelines and
             stable airway obstruction.

          3. Patients with a post-salbutamol FEV1 equal to or greater than 30% of the predicted
             value and less than 80% of the predicted value

          4. Post-salbutamol FEV1/FVC < 70% at screening visit.

          5. Pre-dose FEV1 value of first treatment period within the range of 80-120% of the FEV1
             measured at screening prior to salbutamol inhalation.

          6. Current, or ex-cigarette smokers (former) with a smoking history of at least 10
             pack-years.

          7. Patients whose COPD symptoms at the time of randomisation are stable compared to the
             Screening visit, according to the investigator's medical judgment.

        Exclusion Criteria:

          1. History or current diagnosis of asthma.

          2. A respiratory tract infection or COPD exacerbation in the six weeks prior to the
             screening visit.

          3. Patients who have been hospitalised for an acute COPD exacerbation in the 3 months
             prior to screening visit.

          4. Clinically significant respiratory conditions other than COPD condition.

          5. Clinically significant cardiovascular conditions.

          6. Patients unable to properly use a dry powder or pMDI inhaler device or unable to
             perform acceptable spirometry.

          7. Clinically relevant abnormalities laboratory, ECG parameters or physical examination
             results at the screening evaluation that in the investigator's opinion, preclude study
             participation.

          8. Patients who intend to use any concomitant medication not permitted by this protocol
             or who have not undergone the required washout period for a particular prohibited
             medication.